AkzoNobel Announces 2025 Full-Year Financial Results

AkzoNobel NV, one of the world's leading paints and coatings manufacturers, announced the financial results of its 2025 fiscal year. The company concluded the year with strong cash flow, expanded profit margins and efficiency-focused initiatives.

2025 Fourth Quarter Performance
AkzoNobel's organic sales retreated by 1 percent in the final quarter of 2025 due to declining volumes, while total revenues fell 9 percent due to exchange rate effects. However;

-Operating income rose to EUR 787 million (2024: EUR 127 million),

-Adjusted EBITDA came in at EUR 309 million at constant exchange rates;

-EBITDA margin reached 13.0 percent (2024: 12.3 percent), driven by efficiency programs;

-Net cash flow amounted to EUR 462 million.

The company completed the disposal of Akzo Nobel India Ltd. during the same period, generating approximately EUR 922 million in proceeds, of which EUR 655 million contributed to operating income.

2025 Full-Year Results
AkzoNobel's performance for the full year 2025 also reflects strong financial discipline and efficiency-focused management practices:

-Organic sales remained flat; price/product mix growth was offset by lower volumes,

-Total revenue declined 5 percent to EUR 10.16 billion,

-Adjusted EBITDA came in at EUR 1,444 million; EBITDA margin rose to 14.2 percent (2024: 13.8 percent),

-Operating income reached EUR 1,164 million (2024: EUR 917 million),

-Net cash flow showed significant growth to EUR 915 million compared to the prior year,

-Management is proposing a dividend of EUR 1.54 per share.

Strategic Outlook and Executive Assessment
AkzoNobel Chief Executive Officer Greg Poux-Guillaume commented on the announced results, emphasizing that the company succeeded in improving operational efficiency:

"In a year when markets declined substantially, we increased our profitability by raising our adjusted EBITDA margin to 14.2 percent. This is a testament to our strong operational practices. Furthermore, the proposed merger plan with Axalta carries the potential to create greater value for our customers and shareholders."

The company's CEO noted that market recovery in 2026 could be limited, indicating that particularly the first half of the year may be challenging, while the second half could benefit from more favorable comparison bases.